Name

CanChip

Legal name

CanChip GmbH

Website

https://canchip.org

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

CanChip GmbH is a Potsdam-based biotech startup developing tumor-on-a-chip microfluidic platforms that replicate cancer microenvironments for drug testing and personalized oncology, serving pharmaceutical companies, universities, and research institutions through direct enterprise sales and laboratory services.

Ownership category

akta.pro rank

Product category

Microfluidic Cancer Research Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Microfluidic chip technology
• Tumor microenvironment modeling
• Cancer drug screening
• Organ-on-chip platforms
• Preclinical drug testing

Headquarters

HQ city

Potsdam

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Chip Platform Sales: Sale of Tumor-on-a-Chip, Organ-on-a-Chip, and Multi-Organ-on-a-Chip platforms along with microfluidic accessories. Platforms are sold directly to pharmaceutical companies, universities, and research institutions for drug testing and cancer research applications.
2. Laboratory Testing Services: Fee-for-service laboratory testing including drug effectiveness testing, metastasis simulation, genomic profiling, microenvironment interaction studies, drug combination screening, biomarker expression profiling, and long-term culture monitoring.
3. Consulting and Technical Support: Expert consulting services for tumor-on-a-chip research including experimental design, technology integration, troubleshooting, maintenance, data analysis, literature review, grant and manuscript support.
4. Training and Workshops: Customizable training programs and workshops on tumor-on-a-chip technology covering fundamentals, experimental design, and data analysis, targeting researchers, industry professionals, and students.
5. Customization Services: Bespoke tumor-on-chip configurations tailored to specific cancer research requirements, including personalized cell types, fluidic conditions, biomarkers, cell lines, and experimental parameters.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

CanChip develops and sells microfluidic tumor-on-a-chip platforms (Tumor-on-a-Chip, Organ-on-a-Chip, Multi-Organ-on-a-Chip, and Bioprinting Chips) that authentically replicate the 3D tumor microenvironment for cancer research, drug screening, and personalized oncology applications. The company also provides microfluidic system accessories, customization services, in-house laboratory testing (drug effectiveness, metastasis simulation, genomic and biomarker profiling), consulting, research support, and training workshops. Customers are pharmaceutical companies, universities, research institutions, and hospitals.

Product overview

CanChip offers a portfolio of microfluidic tumor-on-a-chip products and services for cancer research. The core product line consists of Tumor-on-a-Chip (ToC/CoC) platforms, Organ-on-a-Chip (OoC) systems, Multi-Organ-on-a-Chip (MOoC) platforms, and Bioprinting Chips—all based on cutting-edge microfluidic technology that authentically replicates tumor microenvironments. These platforms are complemented by Customization Services and Microfluidic System Accessories (cell-free chips, porous membranes, chip design). The company also provides an ecosystem of laboratory services including specialized lab facilities (microfluidic, genomics, cell culture), laboratory testing services (drug effectiveness, metastasis simulation, genomic profiling, biomarker expression), and technical/consulting/research support. Training and workshops round out the service offerings. This integrated approach enables pharmaceutical companies and researchers to perform drug testing, personalized medicine studies, and cancer biology research with human-relevant, ethically superior alternatives to traditional methods.

Differentiator

Problem solved

Functional benefit

Products and services

• Tumor-on-a-Chip (ToC/CoC) A microfluidic platform that faithfully recreates realistic 3D tumor microenvironments, including blood vessels and tumor microenvironment components, for drug testing and cancer research. Versatile across various cancer types, it offers a streamlined, cost-effective alternative to traditional 2D cell cultures and animal models and supports studies of tumor growth, metastasis, drug responses, and immune system interactions.
• Organ-on-a-Chip (OoC) An innovative microfluidic system that mimics physiological conditions of human organs, providing a dynamic environment for cellular studies with precision-engineered microfluidic channels recreating organ function complexity. Features real-time monitoring and high-throughput compatibility for drug response and disease mechanism studies.
• Multi-Organ-on-a-Chip (MOoC) A platform integrating multiple organ modules on a single chip to simulate inter-organ communication and human body dynamics, providing a holistic approach to drug testing and disease modeling with precise control over diverse microenvironments.
• Bioprinting Chips Chips that fuse 3D bioprinting with microfluidic platforms to recreate intricate tumor models on a microscale, replicating structural complexities of tumors and enabling exploration of cell-cell interactions and drug responses with high accuracy.
• Microfluidic System Accessories A curated line of components for microfluidic platforms including cell-free chips (CfC), porous membranes, and chip design services, sold for seamless integration into and customization of CanChip's tumor-on-a-chip platforms.
• Laboratory Testing Services Fee-for-service laboratory testing using CanChip's in-house microfluidic, genomics, and cell culture laboratories, including drug effectiveness testing, metastasis simulation, genomic profiling, microenvironment interaction studies, drug combination screening, biomarker expression profiling, and long-term culture monitoring for pharmaceutical and academic customers.
• Consulting Services Expert consulting for drug response studies on tumor-on-a-chip platforms, including experimental design optimization, metastasis investigation guidance, and genomic research interpretation for pharmaceutical companies and academic researchers.
• Technical and Lab Support Technical support services covering experimental design and optimization, technology integration assistance, and troubleshooting and maintenance for tumor-on-chip systems used by pharmaceutical and academic customers.
• Research Support Services Research assistance including data analysis and interpretation, literature review and trend analysis, and grant and manuscript preparation support for researchers using CanChip's platforms.
• Training and Workshops Customizable training programs and workshops on tumor-on-a-chip technology covering fundamentals, experimental design and optimization, and data analysis and interpretation, targeting researchers, industry professionals, and students.
• Customization Services for Tumor-on-Chip Bespoke tumor-on-chip configuration services that tailor CanChip platforms to mimic specific tumor microenvironments, including integration of unique biomarkers, cell lines, fluidic conditions, and experimental parameters for personalized oncology research.

Quantifiable outcome

• Dose-dependent cellular and molecular responses consistent with clinical data in CRC-on-a-Chip studies with 5-FU
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Fraunhofer Institute for Applied Polymer Research (IAP)coreTechnology or IntegrationCanChip collaborates with Fraunhofer IAP on validating drug absorption in 3D-printed microfluidic devices. Joint external quality report tested device performance using 5-Fluorouracil (5FU) over 72 hours using UV-Vis spectrophotometry. Partnership validates precision and reliability of CanChip's chips for pharmaceutical research applications.
• Fraunhofer Institute for Cell Therapy and Immunology – Branch Bioanalytic and Bioprocesses (IZI-BB)coreStrategic or Co-development PartnerLocated in Potsdam-Golm, Fraunhofer IZI-BB provides state-of-the-art infrastructure for miniaturization and automation of biological processes including biosensor technologies, pipetting robots, and rapid-prototyping. The collaboration supports CanChip's research in biomedicine, diagnostics, and biotechnology applications.
• Dr. Clive RoperminorOthersDr. Clive Roper, PhD in in vitro dermal metabolism and toxicology from Newcastle University, provides expert consulting in optimal marketing and commercialization of tumor-on-chip technology. He is board chairperson of PeptiMatrix, board member of 3Rs Collaborative and NC3Rs, and Vice President of ESTIV, supporting regulatory acceptance and NAM (New Approach Methodologies) adoption.
• Preclinic GmbHminorStrategic or Co-development PartnerCanChip CEO Ghazaleh Madani conducted her master's thesis research at Preclinic GmbH from May 2022 to February 2023, working on a research and development project with an immunization and antibody production base. Indicates prior collaborative research relationship.
• Universities and Research InstitutionscoreStrategic or Co-development PartnerCanChip actively collaborates with universities for joint research projects, student theses (PhD and Master's), and postdoc projects in cancer biology and tumor-on-chip applications. The company cooperates with scientific and research centers, and professors to advance personalized medicine in cancer biology. Co-development of chip models and shared publication of research findings.
• Pharmaceutical CompaniescoreStrategic or Co-development PartnerCanChip works with pharmaceutical companies for drug screening, preclinical testing, and development of personalized treatment strategies. Partnerships aimed at enabling pharma companies to evaluate drug efficacy and safety using patient-relevant tumor-on-chip models, reducing animal testing and development costs.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Emulate: Emulate is the leading commercial organ-on-chip platform (Human Emulation System) used across pharma R&D and academia for liver, lung, gut, and brain models. It directly overlaps with CanChip's OoC/MOoC technology category and serves the same pharma buyer, but operates at vastly larger scale across multiple organ indications versus CanChip's oncology focus.

Direct peers

• TissUse: TissUse is a Berlin-based organ-on-chip company specializing in multi-organ-chip (MOC) systems for ADMET profiling and systemic toxicity testing. Its multi-organ focus and DACH location make it a particularly close regional peer to CanChip's MOoC platform.
• CN Bio: CN Bio offers the PhysioMimix organ-on-chip platform for single- and multi-organ microphysiological systems used in drug discovery and disease modeling. It is a direct competitor to CanChip in the OoC/MOoC category, with established pharma partnerships and a similar go-to-market targeting preclinical researchers.
• InSphero: InSphero provides 3D microtissue and organoid-based disease models for drug discovery and toxicology. While not strictly microfluidic, its 3D cell culture and oncology applications overlap with CanChip's tumor-on-a-chip offering for pharma and academic buyers.
• MIMETAS: MIMETAS develops the OrganoPlate organ-on-chip platform for high-throughput 3D cell culture and disease modeling, including oncology-relevant models. It competes head-to-head with CanChip's OoC and Bioprinting Chips in academic and pharma research channels.

Emerging players

• Kirkstall: Kirkstall is a UK-based organ-on-chip company offering the Quasi Vivo connected cell culture system for multi-organ and toxicology applications. It overlaps with CanChip's MOoC positioning around inter-organ communication.
• SynVivo: SynVivo develops microfluidic tumor-on-a-chip and organ-on-chip platforms that mimic in vivo microenvironments for cancer drug screening and inflammation studies. It is a close technology peer to CanChip in the tumor-on-chip niche specifically.
• Nortis Bio: Nortis Bio (formerly Nortis) provides microfluidic organ-on-chip systems for kidney, vascular, and cancer applications. Its tumor-vascular and angiogenesis-on-chip work directly parallels CanChip's CRC-on-a-Chip approach.
• Hurel Corporation: Hurel develops microfluidic liver-on-chip and other tissue-on-chip platforms for ADMET and toxicology testing used by pharma companies. It is a comparable microfluidic preclinical platform vendor, although with different primary organ focus than CanChip.

Others

• CellFE.ai: CellFE.ai uses microfluidic-based cell engineering for cell therapy and gene therapy manufacturing. While not a tumor-on-chip competitor, it sits in the same microfluidic biotech infrastructure ecosystem serving next-generation cell-based therapies and is adjacent to CanChip's technology stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/canchip

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CanChip